229 related articles for article (PubMed ID: 35008001)
1. Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development.
Zhang T; Zhou H; Wang K; Wang X; Wang M; Zhao W; Xi X; Li Y; Cai M; Zhao W; Xu Y; Shao R
Biomed Pharmacother; 2022 Mar; 147():112616. PubMed ID: 35008001
[TBL] [Abstract][Full Text] [Related]
2. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties.
Liu S; Sun Y; Hou Y; Yang L; Wan X; Qin Y; Liu Y; Wang R; Zhu P; Teng Y; Liu M
J Hematol Oncol; 2021 Oct; 14(1):178. PubMed ID: 34715882
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
4. Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment.
Pires BR; DE Amorim ÍS; Souza LD; Rodrigues JA; Mencalha AL
Anticancer Res; 2016 Nov; 36(11):5681-5691. PubMed ID: 27793889
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells.
Yousefnia S; Seyed Forootan F; Seyed Forootan S; Nasr Esfahani MH; Gure AO; Ghaedi K
Front Oncol; 2020; 10():452. PubMed ID: 32426267
[TBL] [Abstract][Full Text] [Related]
7. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium.
Feng ZM; Qiu J; Chen XW; Liao RX; Liao XY; Zhang LP; Chen X; Li Y; Chen ZT; Sun JG
BMC Cancer; 2015 Sep; 15():645. PubMed ID: 26400441
[TBL] [Abstract][Full Text] [Related]
8. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells.
Pavlopoulou A; Oktay Y; Vougas K; Louka M; Vorgias CE; Georgakilas AG
Cancer Lett; 2016 Oct; 380(2):485-493. PubMed ID: 27450721
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.
Ali K; Nabeel M; Mohsin F; Iqtedar M; Islam M; Rasool MF; Hashmi FK; Hussain SA; Saeed H
Med Oncol; 2024 Apr; 41(5):112. PubMed ID: 38592510
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapeutics Against Breast Cancer Stem Cells by Targeting Surface Markers and Signaling Pathways.
Das PK; Rakib MA; Khanam JA; Pillai S; Islam F
Curr Stem Cell Res Ther; 2019; 14(8):669-682. PubMed ID: 31808385
[TBL] [Abstract][Full Text] [Related]
12. The interplay between IGF-1R signaling and Hippo-YAP in breast cancer stem cells.
Chan YT; Lin RJ; Wang YH; Hung TH; Huang Y; Yu J; Yu JC; Yu AL
Cell Commun Signal; 2023 Apr; 21(1):81. PubMed ID: 37081542
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer stem cells as novel biomarkers.
Ray SK; Mukherjee S
Clin Chim Acta; 2024 Apr; 557():117855. PubMed ID: 38453050
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity and Plasticity of Breast Cancer Stem Cells.
Sousa B; Ribeiro AS; Paredes J
Adv Exp Med Biol; 2019; 1139():83-103. PubMed ID: 31134496
[TBL] [Abstract][Full Text] [Related]
15. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
16. A novel Lnc408 maintains breast cancer stem cell stemness by recruiting SP3 to suppress CBY1 transcription and increasing nuclear β-catenin levels.
Wen S; Qin Y; Wang R; Yang L; Zeng H; Zhu P; Li Q; Qiu Y; Chen S; Liu Y; Hou Y; Tang X; Liu M; Tu G
Cell Death Dis; 2021 May; 12(5):437. PubMed ID: 33934099
[TBL] [Abstract][Full Text] [Related]
17. Advances in Biomarkers and Endogenous Regulation of Breast Cancer Stem Cells.
Chen W; Zhang L; Liu S; Chen C
Cells; 2022 Sep; 11(19):. PubMed ID: 36230903
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cell-immune cell crosstalk in breast tumor microenvironment: a determinant of therapeutic facet.
Guha A; Goswami KK; Sultana J; Ganguly N; Choudhury PR; Chakravarti M; Bhuniya A; Sarkar A; Bera S; Dhar S; Das J; Das T; Baral R; Bose A; Banerjee S
Front Immunol; 2023; 14():1245421. PubMed ID: 38090567
[TBL] [Abstract][Full Text] [Related]
19. SURVIVIN as a marker for quiescent-breast cancer stem cells-An intermediate, adherent, pre-requisite phase of breast cancer metastasis.
Siddharth S; Das S; Nayak A; Kundu CN
Clin Exp Metastasis; 2016 Oct; 33(7):661-75. PubMed ID: 27411340
[TBL] [Abstract][Full Text] [Related]
20. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
